AIM: To prospectively assess the antibacterial resistance rate in Helicobacter pylori strains obtained from symptomatic children in Europe. METHODS: During a 4-year period, 17 paediatric centres from 14 European countries reported prospectively on patients infected with H pylori, for whom antibiotic susceptibility was tested. RESULTS: A total of 1233 patients were reported from Northern (3%), Western (70%), Eastern (9%) and Southern Europe (18%); 41% originated from outside Europe as indicated by mother's birth-country; 13% were <6 years of age, 43% 6-11 years of age and 44% >11 years of age. Testing was carried out before the first treatment (group A, n = 1037), and after treatment failure (group B, n = 196). Overall resistance to clarithromycin was detected in 24% (mean, A: 20%, B: 42%). The primary clarithromycin resistance rate was higher in boys (odds ratio (OR) 1.58; 1.12 to 2.24, p = 0.01), in children <6 years compared with >12 years (OR 1.82, 1.10 to 3.03, p = 0.020) and in patients living in Southern Europe compared with those living in Northern Europe (OR 2.25; 1.52 to 3.30, p<0.001). Overall resistance rate to metronidazole was 25% (A: 23%, B: 35%) and higher in children born outside Europe (A: adjusted. OR 2.42, 95% CI: 1.61 to 3.66, p<0.001). Resistance to both antibiotics occurred in 6.9% (A: 5.3%, B: 15.3%). Resistance to amoxicillin was exceptional (0.6%). Children with peptic ulcer disease (80/1180, 6.8%) were older than patients without ulcer (p = 0.001). CONCLUSION: The primary resistance rate of H pylori strains obtained from unselected children in Europe is high. The use of antibiotics for other indications seems to be the major risk factor for development of primary resistance.
AIM: To prospectively assess the antibacterial resistance rate in Helicobacter pylori strains obtained from symptomatic children in Europe. METHODS: During a 4-year period, 17 paediatric centres from 14 European countries reported prospectively on patients infected with H pylori, for whom antibiotic susceptibility was tested. RESULTS: A total of 1233 patients were reported from Northern (3%), Western (70%), Eastern (9%) and Southern Europe (18%); 41% originated from outside Europe as indicated by mother's birth-country; 13% were <6 years of age, 43% 6-11 years of age and 44% >11 years of age. Testing was carried out before the first treatment (group A, n = 1037), and after treatment failure (group B, n = 196). Overall resistance to clarithromycin was detected in 24% (mean, A: 20%, B: 42%). The primary clarithromycin resistance rate was higher in boys (odds ratio (OR) 1.58; 1.12 to 2.24, p = 0.01), in children <6 years compared with >12 years (OR 1.82, 1.10 to 3.03, p = 0.020) and in patients living in Southern Europe compared with those living in Northern Europe (OR 2.25; 1.52 to 3.30, p<0.001). Overall resistance rate to metronidazole was 25% (A: 23%, B: 35%) and higher in children born outside Europe (A: adjusted. OR 2.42, 95% CI: 1.61 to 3.66, p<0.001). Resistance to both antibiotics occurred in 6.9% (A: 5.3%, B: 15.3%). Resistance to amoxicillin was exceptional (0.6%). Children with peptic ulcer disease (80/1180, 6.8%) were older than patients without ulcer (p = 0.001). CONCLUSION: The primary resistance rate of H pylori strains obtained from unselected children in Europe is high. The use of antibiotics for other indications seems to be the major risk factor for development of primary resistance.
Authors: P Bontems; J M Devaster; L Corvaglia; A Dezsöfi; C Van Den Borre; S Goutier; J P Butzler; S Cadranel Journal: Pediatr Infect Dis J Date: 2001-11 Impact factor: 2.129
Authors: J Crone; G Granditsch; W-D Huber; C Binder; A Innerhofer; G Amann; A M Hirschl Journal: J Pediatr Gastroenterol Nutr Date: 2003-03 Impact factor: 2.839
Authors: W L Peterson; D Y Graham; B Marshall; M J Blaser; R M Genta; P D Klein; C W Stratton; J Drnec; P Prokocimer; N Siepman Journal: Am J Gastroenterol Date: 1993-11 Impact factor: 10.864
Authors: S Koletzko; N Konstantopoulos; D Bosman; A Feydt-Schmidt; A van der Ende; N Kalach; J Raymond; H Rüssmann Journal: Gut Date: 2003-06 Impact factor: 23.059
Authors: Brian J McMahon; Thomas W Hennessy; J Michael Bensler; Dana L Bruden; Alan J Parkinson; Julie M Morris; Alisa L Reasonover; Debby A Hurlburt; Michael G Bruce; Frank Sacco; Jay C Butler Journal: Ann Intern Med Date: 2003-09-16 Impact factor: 25.391
Authors: Teresa Alarcón; Alba E Vega; Diego Domingo; Maria Josefa Martínez; Manuel López-Brea Journal: J Clin Microbiol Date: 2003-01 Impact factor: 5.948
Authors: William M Duck; Jeremy Sobel; Janet M Pruckler; Qunsheng Song; David Swerdlow; Cindy Friedman; Alana Sulka; Balasubra Swaminathan; Tom Taylor; Mike Hoekstra; Patricia Griffin; Duane Smoot; Rick Peek; David C Metz; Peter B Bloom; Steven Goldschmidt; Julie Parsonnet; George Triadafilopoulos; Guillermo I Perez-Perez; Nimish Vakil; Peter Ernst; Steve Czinn; Donald Dunne; Ben D Gold Journal: Emerg Infect Dis Date: 2004-06 Impact factor: 6.883
Authors: Lucia Pacifico; John Frederick Osborn; Enea Bonci; Sara Romaggioli; Rossella Baldini; Claudio Chiesa Journal: World J Gastroenterol Date: 2014-01-21 Impact factor: 5.742
Authors: Sarah Talarico; Benjamin D Gold; Jutta Fero; Dexter T Thompson; Jeannette Guarner; Steven Czinn; Nina R Salama Journal: J Clin Microbiol Date: 2009-04-22 Impact factor: 5.948